Among those with no pre-existing fractures, compute the relative risk of new fractures among those randomized to raloxifene vs. placebo, along with its associated 95% CI?

Endocrinology

A study of raloxifene and incidence of fractures was conducted among women with evidence of osteoporosis. The women were initially divided into two groups: those with and those without pre-existing fractures. The women were then randomized to raloxifene or placebo and followed for 3 years to determine the incidence of new vertebral fractures, with the results shown in Table 13.53.

Table 13.53 Comparison of fracture incidence between raloxifene- and placebo-treated women

 

Transcribed Image Text:

No pre-existing fractures Pre-existing fractures No new fractures No new fractures Total New fractures New fractures Total Raloxifene Raloxifene Placebo 1466 1432 34 68 103 170 597 630 1500 1500 700 800 Placebo Total 2898 1227 1500 102 273 3000 Total